7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Exelixis Inc. (EXEL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 23,439,500 | $780,535,350 | -8% | 3.95% |
| 2. | Renaissance Technologies Jim Simons | 15,295,865 | $509,352,305 | -1% | 0.75% |
| 3. | AQR Capital Management Cliff Asness | 3,967,005 | $132,101,266 | +26% | 0.17% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,159,395 | $105,207,854 | +105% | 0.08% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,627,890 | $54,208,737 | -5% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.76 | 225,000 | Director | 1,525,730 | 2024-05-30 | Filing | |
| $20.32 | 200,000 | Director | 1,300,730 | 2024-05-28 | Filing | |
| $20.70 | 190,000 | Director | 1,100,730 | 2024-02-21 | Filing | |
| $21.61 | 120,409 | Director | 910,730 | 2023-11-27 | Filing | |
| $4.95 | 20,000 | Director | 568,273 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.80 | 10,000 | Officer | 341,028 | 2025-03-03 | Filing | |
| $37.62 | 19,294 | Director | 10,778 | 2025-02-28 | Filing | |
| $38.13 | 54,514 | Director | 10,778 | 2025-02-27 | Filing | |
| $37.80 | 8,768 | Director | 356,605 | 2025-02-28 | Filing | |
| $36.98 | 52,636 | Officer | 303,310 | 2025-02-24 | Filing |
Institutional Investors' Holdings
News See All
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today.
What Makes Exelixis (EXEL) an Investment Bet?
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Exelixis Third Quarter 2024 Financial Results Conference Call. My name is Towanda, and I will be your operator for today.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.